Digg icon reddit icon Stumbleupon icon
Print Email     Print Edition Stories

Wednesday, June 4, 2008

Insulet pump picked for first non-insulin use

By Mass High Tech Staff


Insulet Corp., a maker of wearable insulin pumps, reports it has entered into its first agreement to develop its technology outside of the field of diabetes care.

The Bedford-based medical devices company said that Swiss drug company Ferring Pharmaceuticals plans to adapt Insulet’s OmniPod system — which is an insulin-injecting device worn over the skin — to deliver a Ferring treatment for women’s health.

Insulet (Nasdaq: PODD) didn’t disclose financing details of the deal or which Ferring drug the Swiss firm plans to inject with OmniPods. Ferring, which has a U.S. subsidiary based in New Jersey, markets several female fertility treatments taken by injection. A call to Insulet was not immediately returned before press time this morning.

Insulet, which employs 247 workers, reported a 2007 net loss of $53.5 million on revenue of $13.4 million. The company completed an $115.5 million initial public offering in May 2007.

Comments

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.

Digg icon reddit icon Stumbleupon icon
Contact Editor Latest News

Tech Pulse Poll

What's your level of interest in Pinterest?



View Results

Stay Informed
Check which newsletter you'd like to receive.
TechFlash (Daily)
BioFlash (Daily)
GreenFlash (Weekly)
Startup Report (Weekly)
Breaking news, MHT events, local announcements
RSS feeds
Your email:

Affiliate publications: ACBJ.com, Boston Business Journal, Bizjournals.com, Portfolio.com, Wired.com

Web Site Developed by Neptune Web, Inc.

Use of and/or registration on any portion of this site constitutes acceptance of our User Agreement and Privacy Policy. About our ads.